Cloud-based insulin management software developer Glytec announced today that it appointed Nausheen Moulana as its chief technology officer.
In the role of CTO, Moulana will be responsible for Glytec’s product and technology vision, strategy and execution. She will lead the company’s product development teams — focusing on enhancements in provider workflows, electronic health record (EHR) integrations, mobile apps and support for other diabetes technologies.
A more-than-25-year veteran in engineering and operations roles, Moulana previously served as VP of engineering & operations at Kyruus, leading multiple teams tasked with delivering multi-channel patient access solutions. She also held leadership roles at Attivio (since acquired by ServiceNow) and MathWorks, according to a news release.
Waltham, Mass.-based Glytec develops the eGlycemic Management System (eGMS) for managing insulin. It is centered around the FDA-cleared Glucommander software, which uses real-time and historical data to recommend insulin dosing by learning each patient’s insulin sensitivity and anticipating future needs. The personalized treatment regime can reduce hypoglycemia, hyperglycemia, lengths of stay, readmissions and cost of care.
“Thousands of hospitals across the country still rely on dated paper protocols to titrate insulin and manage inpatient blood glucose levels. The opportunity for advanced software to simplify these processes and improve patient safety and care is massive,” Moulana said in the release. “I’m honored to join the growing team at Glytec to address this challenge and further revolutionize the way providers care for patients that require insulin in the hospital setting.”
Glytec launched the eGMS in March and followed the launch with a $21 million financing round in April. The funds are earmarked for research and development around patient safety, provider workflows and analytics for the eGMS — and for adding talent to the workforce and enhancing integrations with EHRs, mobile apps and other diabetes care technologies ranging across the continuum of care.
“This has been a record year for Glytec and adding a proven technology leader like Nausheen to the Executive team only builds upon that momentum,” Glytec president & CEO Ed Furlong said. “The past year has illuminated the importance of properly managing glycemic issues, especially in the hospital setting.
